Related Experiment Video
Updated: May 12, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
IL-10 promoter polymorphisms affect IL-10 production and associate with susceptibility to acute myeloid leukemia
Yao Chenjiao1, Fan Zili, Chen Haibin
1Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, China.
Abstract:
We investigated the possible association of Interleukin-10 (IL-10) single nucleotide polymorphisms (SNPs) and susceptibility to acute myeloid leukemia (AML) in 115 AML patients and 137 gender- and age-matched controls. Genetic analysis of IL-10 SNPs at -819 and -592 was carried out by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results revealed that the -819AA genotype frequencies and the -819A allele frequencies of AML group were higher than the controls (59.1% vs 40.9%; 75.6% vs 63.9%, respectively); there were remarkable differences in -819T/C and -592A/C gene distribution (P<0.05) and the TA haploid frequencies were higher in AML group (75.6% vs 63.9%, P<0.05). The IL-10 mRNA expression of AML patients and controls with different genotype was detected by Real-time quantitative Polymerase Chain Reaction (RT-PCR). IL-10 mRNA expression in incipient AML patients increased obviously compared with the non-tumor group and remission group (P<0.05). Further analysis suggested that the IL-10 mRNA expression of TA/TA genotype was the lowest and CC/CC genotype was the highest; the haploid TA and genotype TA/TA may be associated with AML. The research suggested the IL-10 SNPs at -819 and -592 sites were associated with AML and may affect the IL-10 mRNA expression in AML patients in Han people of Hunan province.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Lineage Commitment
Non-LTR Retrotransposons
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
